BioCryst Compound Ineffective Against Psoriasis In Phase II Dosing Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Data show potential against T-cell and B-cell mediated disease, however.
You may also be interested in...
BioCryst Partners With Shionogi On Influenza Antiviral In Japan
Shionogi gains development and commercialization rights for peramivir in Japan in deal worth up to $130 million plus royalties for BioCryst.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.